Jazz Pharmaceuticals (JAZZ) Current Assets (2010 - 2026)
Jazz Pharmaceuticals (JAZZ) posted quarterly Current Assets of $4.6 billion for Q1 2026, up 11.03% year-over-year from $4.1 billion in Q1 2025, and up 10.01% quarter-over-quarter from $4.2 billion in Q4 2025.
Jazz Pharmaceuticals (JAZZ) Current Assets (2010 - 2026) Analysis & Trends
Jazz Pharmaceuticals' Current Assets history runs 17 years deep, the most recent figure standing at $4.6 billion for Q1 2026.
- In Q1 2026, Current Assets rose 11.03% year-over-year to $4.6 billion; the TTM figure through Mar 2026 stood at $4.6 billion (up 11.03% YoY), while the FY2025 annual figure was $4.2 billion, down 10.0% from the prior year.
- Current Assets for Q1 2026 stood at $4.6 billion, up from $4.2 billion in the prior quarter.
- The five-year high for Current Assets was $4.6 billion in Q4 2024, with the low at $2.5 billion in Q1 2022.
- The 5-year median for Current Assets is $3.4 billion (2023), against an average of $3.5 billion.
- The sharpest annual moves came in 2022 and 2024: Current Assets declined 21.03% in 2022, then jumped 35.27% in 2024.
- Jazz Pharmaceuticals' Current Assets stood at $2.6 billion in 2022, then surged by 31.82% to $3.4 billion in 2023, then surged by 34.74% to $4.6 billion in 2024, then decreased by 10.0% to $4.2 billion in 2025, then grew by 10.01% to $4.6 billion in 2026.
- Business Quant data shows JAZZ's Current Assets at $4.6 billion in Q1 2026, $4.2 billion in Q4 2025, and $3.8 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Jazz Pharmaceuticals | 15.90 Bn | 14.28 Bn | 1.09 Bn | 3.97 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.97 Bn |
| Mar 31, 2026 | 4.58 Bn |
| Dec 31, 2025 | 4.17 Bn |
| Sep 30, 2025 | 3.76 Bn |
| Jun 30, 2025 | 3.35 Bn |
| Mar 31, 2025 | 4.13 Bn |
| Dec 31, 2024 | 4.63 Bn |
| Sep 30, 2024 | 4.39 Bn |
| Jun 30, 2024 | 3.68 Bn |
| Mar 31, 2024 | 3.54 Bn |
| Dec 31, 2023 | 3.44 Bn |
| Sep 30, 2023 | 3.25 Bn |
| Jun 30, 2023 | 3.01 Bn |
| Mar 31, 2023 | 2.78 Bn |
| Dec 31, 2022 | 2.61 Bn |
| Sep 30, 2022 | 2.57 Bn |
| Jun 30, 2022 | 2.59 Bn |
| Mar 31, 2022 | 2.50 Bn |
| Dec 31, 2021 | 2.61 Bn |
| Sep 30, 2021 | 2.63 Bn |